Sanjay Kumar Raul

About

Dr. Sanjay Kumar Raul is currently working as an Assistant Professor in P.G. Department of Biotechnology, Rama Devi Women’s University, India. He received his Ph.D. in Molecular Medicine from Georg-August-University, Gottingen, Germany and was a Post-doctoral researcher at Indian Institute of Science, Bengaluru, India. His research interests include Identification and characterization of Small molecule inhibitors in cancer treatment, Understanding the molecular mechanism(s) of DNA Double strand Break Repair process in different cancer for improved cancer therapy, Mammalian cell culture and Animal model system.

Employment

• Rama Devi Women's University Assistant Professor
  2018 - Present
• IMGENEX India (India) Research Scientist
  2006 - 2012
• Council of Scientific and Industrial Research Institute of Minerals and Materials Technology Project Assistant
  2005 - 2006

Education

• Indian Institute of Science Post Doctoral Fellow
  2017 - 2028

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• Therapeutic Advancement in Cardiovascular Disorders: Molecular Mechanisms, Emerging Targets and Translational Perspectives
  Journal of Drug Delivery and Therapeutics 2026 DOI: 10.22270/jddt.v16i7.7825
  +Save
• Advancement in Green nano-formulation for management of Gynaecological disorders: Emerging trends and Therapeutic insights
  Journal of Drug Delivery and Therapeutics 2026 DOI: 10.22270/jddt.v16i5.7738
  +Save
• A Comprehensive Ethnophytopharmacological Review on Antileucorrhoeal Medicinal Plants From the Indian Tribal Region: Towards Future Therapeutic Research
  Journal of Herbal Medicine 2024 DOI: 10.1016/j.hermed.2024.100925
  +Save
• Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics
  Molecular Carcinogenesis 2020 DOI: 10.1002/MC.23186
  +Save
• The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness
  Clinical Epigenetics 2019 DOI: 10.1186/S13148-018-0601-1
  +Save
• Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness (vol 17, pg 1609, 2016)
  EMBO Reports 2018
  +Save
• Corrigendum to: Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness (EMBO reports, (2016), 17, 11, (1609-1623), 10.15252/embr.201642352)
  EMBO Reports 2016 DOI: 10.15252/embr.201846783
  +Save
• Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
  EMBO Reports 2016 DOI: 10.15252/EMBR.201642352
  +Save
• Pancreatic cancer screening by TLR phenotyping
  Cancer Research 2011 DOI: 10.1158/1538-7445.AM2011-894
  +Save